Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $2.41.

  • Harvard Bioscience's Debt to Equity rose 31660.71% to $2.41 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.41, marking a year-over-year increase of 31660.71%. This contributed to the annual value of $0.58 for FY2024, which is 1660.79% up from last year.
  • Per Harvard Bioscience's latest filing, its Debt to Equity stood at $2.41 for Q3 2025, which was up 31660.71% from $2.22 recorded in Q2 2025.
  • Harvard Bioscience's 5-year Debt to Equity high stood at $2.42 for Q1 2025, and its period low was $0.5 during Q4 2023.
  • In the last 5 years, Harvard Bioscience's Debt to Equity had a median value of $0.58 in 2024 and averaged $0.86.
  • Its Debt to Equity has fluctuated over the past 5 years, first plummeted by 2378.32% in 2023, then soared by 36838.2% in 2025.
  • Over the past 5 years, Harvard Bioscience's Debt to Equity (Quarter) stood at $0.58 in 2021, then increased by 11.88% to $0.65 in 2022, then decreased by 22.83% to $0.5 in 2023, then grew by 16.61% to $0.58 in 2024, then soared by 313.83% to $2.41 in 2025.
  • Its Debt to Equity stands at $2.41 for Q3 2025, versus $2.22 for Q2 2025 and $2.42 for Q1 2025.